These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25893808)

  • 1. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
    Powell KL; Stephens AS; Ralph SJ
    Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
    Dezfouli S; Hatzinisiriou I; Ralph SJ
    Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
    Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
    Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes.
    Wang R; Freywald A; Chen Y; Xu J; Tan X; Xiang J
    Cell Mol Immunol; 2015 Jul; 12(4):456-65. PubMed ID: 25195511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
    Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
    J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
    Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
    Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
    Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
    J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects.
    Park HM; Sohn HJ; Kim YJ; Cho HI; Kim TG
    Vaccine; 2014 Dec; 32(51):6919-6926. PubMed ID: 25444817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
    Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
    Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
    Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
    Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
    Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
    Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
    Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H
    Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.
    Yi H; Guo C; Yu X; Gao P; Qian J; Zuo D; Manjili MH; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2011 Nov; 71(21):6611-20. PubMed ID: 21914786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses.
    Umeshappa CS; Huang H; Xie Y; Wei Y; Mulligan SJ; Deng Y; Xiang J
    J Immunol; 2009 Jan; 182(1):193-206. PubMed ID: 19109150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
    Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
    Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL.
    Serghides L; Bukczynski J; Wen T; Wang C; Routy JP; Boulassel MR; Sekaly RP; Ostrowski M; Bernard NF; Watts TH
    J Immunol; 2005 Nov; 175(10):6368-77. PubMed ID: 16272289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.